IQVIA (NYSE:IQV) Updates FY 2025 Earnings Guidance

IQVIA (NYSE:IQV - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 11.750-12.050 for the period, compared to the consensus earnings per share estimate of 11.835. The company issued revenue guidance of $16.1 billion-$16.3 billion, compared to the consensus revenue estimate of $16.1 billion.

IQVIA Stock Up 3.2%

Shares of IQV traded up $6.17 during trading hours on Thursday, hitting $200.41. The stock had a trading volume of 3,901,081 shares, compared to its average volume of 2,029,690. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.82. The firm has a 50 day simple moving average of $154.75 and a 200-day simple moving average of $170.52. The firm has a market capitalization of $34.67 billion, a P/E ratio of 28.98, a price-to-earnings-growth ratio of 2.21 and a beta of 1.30. IQVIA has a 1-year low of $134.65 and a 1-year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the business posted $2.64 EPS. Sell-side analysts predict that IQVIA will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and dropped their price target for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Evercore ISI raised their price target on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research report on Wednesday, July 9th. Truist Financial raised their price target on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research report on Wednesday. Barclays raised their price target on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Eight analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $227.64.

Institutional Investors Weigh In On IQVIA

A hedge fund recently raised its stake in IQVIA stock. Empowered Funds LLC raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 102.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,728 shares of the medical research company's stock after acquiring an additional 4,915 shares during the quarter. Empowered Funds LLC's holdings in IQVIA were worth $1,715,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 89.62% of the stock is owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.